Information  X 
Enter a valid email address

Deltex Med Grp PLC (DEMG)

  Print          Annual reports

Wednesday 12 January, 2022

Deltex Med Grp PLC

Issue of Equity

RNS Number : 1374Y
Deltex Medical Group PLC
12 January 2022
 

12 January 2022

 

Deltex Medical Group plc

Issue of Equity

 

Deltex Medical Group plc (the "Group" or "Deltex Medical") (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today announces the issue of 2,400,000 ordinary shares (the "New Shares") in connection with the termination agreement of a former employee.

 

Admission

Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. It is expected that admission will take place and dealings in the New Shares will commence on AIM on or around 8.00 a.m. on 17 January 2022.

 

Total voting rights

Immediately following admission, the Company's issued share capital will be 587,343,796 ordinary shares of 1 pence each ("Ordinary Shares"). Deltex Medical does not hold any Ordinary Shares in treasury.  The total voting rights figure, immediately following admission of the New Shares, of 587,343,796 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, Deltex Medical under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

Deltex Medical Group plc   

01243 774 837

Nigel Keen, Chairman  

  [email protected]

Andy Mears, Chief Executive 


Natalie Wettler, Group Finance Director




Nominated Adviser and Broker

Arden Partners plc

0207 614 5900 

Paul Shackleton

  [email protected]

Benjamin Onyeama-Christie 

 


 

Joint Broker


Turner Pope Investments (TPI) Ltd

0203 657 0050

Andy Thacker

James Pope

  [email protected]

 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal Doppler monitoring (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. The technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic monitoring space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.

Clinicians would like to be able to monitor the haemodynamic status of awake patients not only in the operating room and intensive care departments.  Our R&D programmes will provide the capability for Deltex Medical devices to be used in A&E, including, for example, for the rapid detection of sepsis, as well as on lower acuity wards or outside the hospital setting.

Deltex Medical is designing the next generation of non-invasive Doppler ultrasound devices that will be released onto the TrueVue platform and will accurately measure a non-sedated patient's haemodynamic status anywhere within the hospital and not just for elective surgical patients.

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocols for surgical patients, as well as treating ventilated intensive care patients, including ventilated COVID-19 patients. There is also a desire to start measuring haemodynamics on awake patients outside of the operating room or intensive care departments, such as in lower acuity units or in A&E. Our R&D programmes are targeting these broader applications. Consequently, the Group's focus is on maximising value from the opportunities associated with: the COVID-19 pandemic; the elective surgery backlog; the risks associated with sepsis; awake patients and the higher profile of haemodynamic monitoring which has arisen from recent consolidation in the sector.

The Group aims to provide clinicians with a modern, next generation, single 'haemodynamic workstation' platform which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's clinical condition as well as the skill and expertise of the user. Doing this will enable the Group to partner with healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and via agreements with approximately 40 distributors overseas.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFSEFFEESELF

a d v e r t i s e m e n t